BioArctic and Eisai look beyond Leqembi in Alzheimer’s

23 April 2024

Long-term partners BioArctic (Nasdaq Stockholm: BIOA B) and Eisai (TYO: 4523) have announced a new research agreement regarding BAN2802, a potential treatment combining the former company’s proprietary BrainTransporter technology with an undisclosed Alzheimer drug candidate.

At the end of the collaboration, Eisai will evaluate the data generated and decide if whether to exercise an option to license BAN2802 for the treatment of Alzheimer’s disease.

"This technology has huge potential to improve many different projects, and support companies in their pursuit of helping people with brain disorders"The companies have a long-standing collaboration dating back to 2005 regarding the development and commercialization of drugs for the treatment of Alzheimer’s disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK